Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -1130.65% is 122% below its 5-year average of -510.11%, around the middle of its 5-year range (-1915.38%–0.00%).
203.44% below its 12-month average of -372.61%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
OPERATING MARGIN
-1130.65%
OPERATING MARGIN AVG TTM
-372.61%
OPERATING MARGIN AVG 3Y
-739.46%
OPERATING MARGIN AVG 5Y
-510.11%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-203.44%
CURRENT VS 3Y AVG
-52.90%
CURRENT VS 5Y AVG
-121.65%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Taysha Gene Therapies, Inc.
Market Cap
$1.41B
Operating Margin
-1130.65%
TTM Avg
-372.61%
3Y Avg
-739.46%
5Y Avg
-510.11%
Market Cap
$1.39B
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.42B
Operating Margin
20.42%
TTM Avg
-52.76%
3Y Avg
-545.80%
5Y Avg
-384.16%
Market Cap
$1.40B
Operating Margin
5.77%
TTM Avg
5.45%
3Y Avg
4.55%
5Y Avg
4.02%
Market Cap
$1.44B
Operating Margin
-73.77%
TTM Avg
-87.58%
3Y Avg
-121.21%
5Y Avg
-119.21%
Market Cap
$1.44B
Operating Margin
7.03%
TTM Avg
2.87%
3Y Avg
2.90%
5Y Avg
2.58%
Market Cap
$1.37B
Operating Margin
-10386.54%
TTM Avg
-88055.27%
3Y Avg
-48544.96%
5Y Avg
-32630.42%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | $1.41B | -1130.65% | -372.61% | -739.46% | -510.11% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.39B | 0.00% | 0.00% | 0.00% | 0.00% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 20.42% | -52.76% | -545.80% | -384.16% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.40B | 5.77% | 5.45% | 4.55% | 4.02% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | -73.77% | -87.58% | -121.21% | -119.21% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.44B | 7.03% | 2.87% | 2.90% | 2.58% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | -10386.54% | -88055.27% | -48544.96% | -32630.42% |
| Certara, Inc. (CERT)vs › | $1.45B | 1.86% | 2.28% | 0.69% | -0.42% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | 0.00% | 17.19% | 8.60% | 8.60% |
Gross Margin
100.0%
Operating Margin
-1130.7%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | -515.95% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | -1347.08% |
| 2025-03-31 | -930.54% |
| 2024-12-31 | -985.76% |
| 2024-09-30 | -1448.43% |
| 2024-06-30 | -1915.38% |
| 2024-03-31 | -713.28% |
| 2023-12-31 | -450.78% |
| 2023-09-30 | -329.41% |
| 2023-06-30 | -976.37% |
| 2023-03-31 | -351.87% |
| 2022-12-31 | -747.40% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
